ArticleScientific reports2017
Chemotherapeutic efficacies of a clofazimine and diminazene aceturate combination against piroplasm parasites and their AT-rich DNA-binding activity on Babesia bovis.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 31 citations in OpenAlex.
- Genetic resistance to vector-borne hemoprotozoa in livestock: molecular markers, host-parasite interactions, and implications for breeding and control.Journal of veterinary science · 2025Review
- Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects.Nucleic acids research · 2023Article
- DAD3 targets ACE2 to inhibit the MAPK and NF-κB signalling pathways and protect against LPS-induced inflammation in bovine mammary epithelial cells.Veterinary research · 2022Article
- Repurposing of the Malaria Box for Babesia microti in mice identifies novel active scaffolds against piroplasmosis.Parasites & vectors · 2022Article
- Transcriptome Analysis Revealed Potential Mechanisms of Resistance toFrontiers in veterinary science · 2021Article
- Bovine Babesiosis in Turkey: Impact, Current Gaps, and Opportunities for Intervention.Pathogens (Basel, Switzerland) · 2020Review
- Joining forces: Leveraging novel combination therapies to combat infections with eukaryotic pathogens.PLoS pathogens · 2020Article
- Screening the Medicines for Malaria Venture Pathogen Box against piroplasm parasites.International journal for parasitology. Drugs and drug resistance · 2019Article
- Ellagic acid microspheres restrict the growth of Babesia and Theileria in vitro and Babesia microti in vivo.Parasites & vectors · 2019Article
- The effects of trans-chalcone and chalcone 4 hydrate on the growth of Babesia and Theileria.PLoS neglected tropical diseases · 2019Article
- Development of unstable resistance to diminazene aceturate in Babesia bovis.International journal for parasitology. Drugs and drug resistance · 2019Article
- Unravelling the cellular and molecular pathogenesis of bovine babesiosis: is the sky the limit?International journal for parasitology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, we reported that clofazimine (CF) has an anti-piroplasm activity, but it could not completely eliminate parasites in the host. The currently available anti-piroplasm drug, diminazene aceturate (DA), has sometimes been reported to have toxic side effects. In the present study, we evaluated the combination treatment with CF and DA against piroplasms both in vitro and in vivo. Additionally, mRNA level and DNA amounts were analyzed in CF‒ and DA‒treated Babesia bovis by a qPCR. The CF-DA combination had additive effects on Babesia bovis, B. bigemina, and B. caballi and synergistic effects on Theileria equi. The CF-DA combination chemotherapies against B. microti in mice were more potent than their monotherapies. In the CF‒ and DA‒treated B. bovis, CF dose-dependently down-regulated mRNA level and DNA amounts of extranuclear genes (AT-rich featured), whereas DA down-regulated only DNA amounts of extranuclear genes, but those of nuclear genes were slightly down- or up-regulated by CF and DA. In conclusion, the CF-DA combination has a higher efficiency against piroplasms than CF or DA monotherapies. CF and DA might have an AT-rich DNA-binding activity. All results suggest that the CF-DA combination chemotherapy will be a better choice to treat piroplasmosis instead of DA monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.